Edition:
India

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

8.55USD
19 Jan 2018
Change (% chg)

$0.70 (+8.92%)
Prev Close
$7.85
Open
$7.80
Day's High
$8.60
Day's Low
$7.70
Volume
51,405
Avg. Vol
55,453
52-wk High
$8.60
52-wk Low
$2.10

Chart for

About

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of... (more)

Overall

Beta: --
Market Cap(Mil.): $244.85
Shares Outstanding(Mil.): 39.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Strongbridge Biopharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For New Patent Covering RECORLEV

* STRONGBRIDGE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR NEW PATENT COVERING RECORLEV™ (LEVOKETOCONAZOLE) FOR THE TREATMENT OF CUSHING’S SYNDROME

18 Jan 2018

BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS

17 Jan 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

17 Jan 2018

BRIEF-Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis

* STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS

21 Dec 2017

BRIEF-Strongbridge Biopharma Q3 loss per share $0.98

* Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results

14 Nov 2017

BRIEF-Strongbridge Biopharma Plc announces proposed public offering of ordinary shares

* Strongbridge Biopharma Plc announces proposed public offering of ordinary shares

04 Oct 2017

BRIEF-Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma

* Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma Plc as of Sept 12, 2017 - SEC filing Source text: (http://bit.ly/2xlELBz) Further company coverage:

23 Sep 2017

Earnings vs. Estimates